Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Gains from Investment Securities (2018 - 2021)

CNBX Pharmaceuticals (CNBX) has disclosed Gains from Investment Securities for 6 consecutive years, with $195968.0 as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Gains from Investment Securities fell 76.24% year-over-year to $195968.0, compared with a TTM value of -$3.2 million through May 2021, down 552.34%, and an annual FY2024 reading of -$88934.0, changed N/A over the prior year.
  • Gains from Investment Securities was $195968.0 for Q1 2021 at CNBX Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.2 million in Q4 2018 and bottomed at -$3.4 million in Q3 2020.
  • Average Gains from Investment Securities over 4 years is -$207727.3, with a median of $447984.0 recorded in 2019.
  • The sharpest move saw Gains from Investment Securities crashed 167.61% in 2019, then rose 17.84% in 2020.
  • Year by year, Gains from Investment Securities stood at $1.2 million in 2018, then plummeted by 167.61% to -$824849.0 in 2019, then plummeted by 307.63% to -$3.4 million in 2020, then skyrocketed by 105.83% to $195968.0 in 2021.
  • Business Quant data shows Gains from Investment Securities for CNBX at $195968.0 in Q1 2021, -$3.4 million in Q3 2020, and $824849.0 in Q1 2020.